Effectiveness of using metabolomics in combination with MRI for liver metastasis from pancreatic cancer and biliary tract cancer

Effectiveness of using metabolomics in combination with MRI for liver metastasis from pancreatic cancer and biliary tract cancer - Diagnosis of liver metastasis by MRI and metabolomics

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035895

Enrollment

100

Registered

2019-02-17

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastasis

Interventions

Contrast enhanced MRI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who was dagnosed or suspected pancreatic cancer or biliary tract cancer. Patients who evaluate whether liver metastais is present using hepatocyte-specific MRI contrast agent Gd-EOB-DTPA. Over 20 years old.

Exclusion criteria

Exclusion criteria: History of bronchial asthma Renal dysfunction Body contaminants(clips, stents, things embedded during orthopedic surgery) Tattoo Claustrophobia

Design outcomes

Primary

Measure	Time frame
To identificate characteristic radiological findings and low molecular weight metabolites indicating the presence of metastatic liver tumor.	—

Countries

Japan

Contacts

Public ContactKazuhiro Saito

Tokyo Medical University Radiology

saito-k@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026